| Budget Amount *help |
¥26,910,000 (Direct Cost: ¥20,700,000、Indirect Cost: ¥6,210,000)
Fiscal Year 2015: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2014: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2013: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2012: ¥11,440,000 (Direct Cost: ¥8,800,000、Indirect Cost: ¥2,640,000)
|
|---|
| Outline of Final Research Achievements |
The triplex DNA formation against duplex DNA offers a potential basis for genome targeting technology and/or medicine with sequence specificity. In triplex DNA, the sequence-specificity is established via the formation of specific base triplets between a triplex forming oligonucleotide and a duplex DNA, however, there is no natural nucleoside which can recognize inverted sites. The application of the triplex formation is consequently limited to the homopurine-homopyrimidine region of a duplex DNA. We showed the design and synthesis of artificial nucleoside analogues for selective recognition of CG base pair to expand triplex-forming sequence. The 2’-deoxycytidine derivatives were shown to possess high selectivity and affinity toward CG base pair without being effected by neighboring bases. Furthermore, TFO bearing them was demonstrated to effectively inhibit gene expression in living cells.
|
